Syngeneic mouse melanoma (B16F10-muNectin1) with clinical virus: significant anti-tumour effect after one or three intratumoral doses
“Intratumoral administration of a single dose and 3 doses of talimogene laherparepvec produced statistically significant (p<0.0001) anti-tumour effect in the mouse syngeneic melanoma model (Figure 4).”
Human GM-CSF does not bind the mouse GM-CSF receptor, so a murine GM-CSF surrogate virus was used in mice
“A mouse surrogate HSV-1 vector encoding the murine GM-CSF (OncoVEXmGM-CSF; JS1/34.5-/47-/mGM-CSF) was developed and used for the in vivo mouse studies because of the inability of human GM-CSF to bind to mouse GM-CSF receptor.”
FDA: T-VEC shows anti-tumour activity in mice even though encoded human GM-CSF is not biologically active there
“Although human GM-CSF transcript levels were detected in mice, the protein is not biologically active in this species. However, T-VEC displays anti-tumor activity in mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 99Source ↗
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function